Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania and currently employs 21 full-time employees. The company went IPO on 2014-06-27. The firm is engaged in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy utilizes the PoNS device in conjunction with supervised therapeutic exercise. The PoNS Therapy consists of condition-specific exercises for movement control, including balance and gait training and breathing and awareness training, which are tailored to focus on the individual patient’s functional deficits.
Follow-Up Questions
Who is the CEO of Helius Medical Technologies Inc?
Mr. Dane Andreeff is the President of Helius Medical Technologies Inc, joining the firm since 2017.
What is the price performance of HSDT stock?
The current price of HSDT is $5.18, it has decreased 1.04% in the last trading day.
What are the primary business themes or industries for Helius Medical Technologies Inc?
Helius Medical Technologies Inc belongs to Health Care industry and the sector is Health Care
What is Helius Medical Technologies Inc market cap?
Helius Medical Technologies Inc's current market cap is $201.7M
Is Helius Medical Technologies Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Helius Medical Technologies Inc, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell